BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 28974599)

  • 1. Molecular radiotheragnostics in prostate cancer.
    Du Y; Dizdarevic S
    Clin Med (Lond); 2017 Oct; 17(5):458-461. PubMed ID: 28974599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone-targeting radiopharmaceuticals including radium-223.
    Brady D; Parker CC; O'Sullivan JM
    Cancer J; 2013; 19(1):71-8. PubMed ID: 23337760
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Ahmadzadehfar H; Azgomi K; Hauser S; Wei X; Yordanova A; Gaertner FC; Kürpig S; Strunk H; Essler M
    J Nucl Med; 2017 Mar; 58(3):438-444. PubMed ID: 27660148
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Maurer T; Robu S; Schottelius M; Schwamborn K; Rauscher I; van den Berg NS; van Leeuwen FWB; Haller B; Horn T; Heck MM; Gschwend JE; Schwaiger M; Wester HJ; Eiber M
    Eur Urol; 2019 Apr; 75(4):659-666. PubMed ID: 29625755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes: A Meta-analysis of Individual Patient Data From Randomized Clinical Trials.
    Terrisse S; Karamouza E; Parker CC; Sartor AO; James ND; Pirrie S; Collette L; Tombal BF; Chahoud J; Smeland S; Erikstein B; Pignon JP; Fizazi K; Le Teuff G;
    JAMA Oncol; 2020 Feb; 6(2):206-216. PubMed ID: 31830233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
    Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
    BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current Status of Prostate-specific Membrane Antigen-targeted Alpha Radioligand Therapy in Prostate Cancer.
    Yamamichi G; Kato T; Watabe T; Hatano K; Uemura M; Nonomura N
    Anticancer Res; 2024 Mar; 44(3):879-888. PubMed ID: 38423627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted β-emitting radionuclide therapies in metastatic castration-resistant prostate cancer.
    Vlachostergios PJ; Niaz MJ; Skafida M; Mosallaie SA; Thomas C; Christos PJ; Osborne JR; Molina AM; Nanus DM; Bander NH; Tagawa ST
    Prostate; 2021 Apr; 81(5):279-285. PubMed ID: 33465252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Application of Radiolabeled Targeted Molecular Probes for the Diagnosis and Treatment of Prostate Cancer.
    Cheng L; Yang T; Zhang J; Gao F; Yang L; Tao W
    Korean J Radiol; 2023 Jun; 24(6):574-589. PubMed ID: 37271211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Multiple Bone Metastases of Castration-Resistant Prostate Cancer With 225 Ac-PSMA-617.
    Yang H; Zhang Y; Su D; Zhang Y; Chen Y
    Clin Nucl Med; 2023 Dec; 48(12):1078-1081. PubMed ID: 37796187
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Lengana T; Lawal IO; Boshomane TG; Popoola GO; Mokoala KMG; Moshokoa E; Maes A; Mokgoro NP; Van de Wiele C; Vorster M; Sathekge MM
    Clin Genitourin Cancer; 2018 Oct; 16(5):392-401. PubMed ID: 30120038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving
    Sathekge M; Bruchertseifer F; Vorster M; Lawal IO; Knoesen O; Mahapane J; Davis C; Reyneke F; Maes A; Kratochwil C; Lengana T; Giesel FL; Van de Wiele C; Morgenstern A
    J Nucl Med; 2020 Jan; 61(1):62-69. PubMed ID: 31101746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of
    Schwenck J; Rempp H; Reischl G; Kruck S; Stenzl A; Nikolaou K; Pfannenberg C; la Fougère C
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):92-101. PubMed ID: 27557844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of hybrid
    Janssen JC; Meißner S; Woythal N; Prasad V; Brenner W; Diederichs G; Hamm B; Makowski MR
    Eur Radiol; 2018 Feb; 28(2):610-619. PubMed ID: 28779400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Head-To-Head Comparison of
    Zhao G; Ji B
    AJR Am J Roentgenol; 2022 Sep; 219(3):386-395. PubMed ID: 35441529
    [No Abstract]   [Full Text] [Related]  

  • 17. Eligibility for
    Cook GJR; Wong WL; Sanghera B; Mangar S; Challapalli A; Bahl A; Bassett P; Leaning D; Schmidkonz C
    J Nucl Med; 2023 Feb; 64(2):227-231. PubMed ID: 36302657
    [No Abstract]   [Full Text] [Related]  

  • 18. Molecular imaging and biochemical response assessment after a single cycle of [
    Rosar F; Hau F; Bartholomä M; Maus S; Stemler T; Linxweiler J; Ezziddin S; Khreish F
    Theranostics; 2021; 11(9):4050-4060. PubMed ID: 33754047
    [No Abstract]   [Full Text] [Related]  

  • 19. [
    Hofman MS; Violet J; Hicks RJ; Ferdinandus J; Thang SP; Akhurst T; Iravani A; Kong G; Ravi Kumar A; Murphy DG; Eu P; Jackson P; Scalzo M; Williams SG; Sandhu S
    Lancet Oncol; 2018 Jun; 19(6):825-833. PubMed ID: 29752180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Head-to-head comparison of
    Zhang Y; Lin Z; Li T; Wei Y; Yu M; Ye L; Cai Y; Yang S; Zhang Y; Shi Y; Chen W
    Sci Rep; 2022 Sep; 12(1):15993. PubMed ID: 36163353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.